Literature DB >> 7005787

Combined chemotherapy.

A Goldin.   

Abstract

Combined chemotherapy approaches should take into account the complex interrelationships with the host and tumor. Principles of combination drug chemotherapy that may contribute to increased antitumor specificity in the treatment of clinical neoplasia are reviewed and examples provided under the following broad headings: (a) Increased antitumor effectiveness without a proportionate increase in limiting host toxicity. This includes the biochemical concepts of sequential and concurrent blockade, complementary inhibition and error amplification. (b) Decrease in host toxicity without a proportionate loss in antitumor effectiveness. (c) Delay in origin and treatment of resistant mutants. (d) Treatment of metastatic and sequestered tumor cells. (e) Identification of optimal dosages, ratios and schedules for drug combinations. (f) Kinetic considerations such as tumor cell synchronization, choice of drugs that act at different phases of the cell cycle or that stimulate Go cells to divide. (g) Use of drugs that assist active compounds. (h) Employment of combined modalities including surgery, radiation or immunotherapy plus chemotherapy. (i) Loading dose chemotherapy of advanced disseminated tumor. (j) Identification of drugs that may prevent viral or carcinogenic tumor induction. (k) Development of methodology for determination of the effectiveness of polychemotherapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7005787     DOI: 10.1159/000225489

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.

Authors:  Julie Scott; Robert T Dorr; Betty Samulitis; Terry H Landowski
Journal:  Cancer Chemother Pharmacol       Date:  2007-02-28       Impact factor: 3.333

2.  The experimental and clinical implications of cellular heterogeneity in malignant tumors.

Authors:  G Poste; R Greig
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

3.  ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest.

Authors:  George G Chen; Ursula P F Chan; Long-Chuan Bai; King Yip Fung; Art Tessier; Ann K Y To; Juanita L Merchant; Paul B S Lai
Journal:  Cancer Lett       Date:  2009-04-11       Impact factor: 8.679

Review 4.  A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies.

Authors:  Ying Gao; Dongruo Gao; Jie Shen; Qiwen Wang
Journal:  Front Chem       Date:  2020-11-24       Impact factor: 5.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.